Ittigen/Bern, Switzerland (ots) - Pevion Biotech AG today announced latest results from the ongoing clinical study of its therapeutic Candida vaccine PEV7, showing high levels of specific antibodies and a 100% mucosal immune response rate. The announcement further included the results of the largest, international ...
New York (ots) - WISeKey pledged to provide identity management and the necessary transaction platform to enable a new approach of remittances and micro-credit initiatives. WISeKey Founder and CEO Carlos Moreira is in New York this week at the CGI Annual Meeting reporting to President Bill Clinton on the progress ...
Geneva (ots) - WISeKey launches WISeSMS iPhone and Android App for the delivery and receipt of encrypted text messages. WISeSMS encrypts any text and will work with the native delivery platforms on a mobile device to send sensitive and private communications. The application release is accompanied by the launch of ...
Thalia SA (BSI/Generali Group)
Lugano (ots) - The Generali Hedge Fund Sicav Arbitrage Opportunities fund won the World Finance Hedge Fund Award 2011 as the Best Diversified Fund of Hedge Funds, Europe The Generali Hedge Fund Sicav - Arbitrage Opportunities fund, created and managed by Thalìa SA, the company dedicated to Hedge Fund investing within the Generali Group, won the World Financial Hedge Fund Award 2011 as the Best Diversified Fund of Hedge ...
Zurich, Switzerland (ots) - New technology expands treatment options for patient with refractory ascites due to liver cirrhosis. Dr. Farzana Malik joins as Vice President of Market Access and Reimbursement. Sequana Medical announced today that it has received CE Mark approval for the commercial sale of its ALFApump System. Over the coming months, the company will ...
Geneva (ots) - WISeKey launches WISePhone secure phone application for the Blackberry, in addition to its versions available for the iPhone and Android. WISePhone solves the problem of mobile phone security, by encrypting voice communication anywhere in the world, even in regions where eavesdropping is common. The ...
Amsterdam, The Netherlands (ots) - New data presented at the 14th World Conference on Lung Cancer in Amsterdam, The Netherlands, show the efficacy of the 2nd generation 5-HT3 receptor antagonist alone and in combination with aprepitant New data on the 2nd generation 5-HT3 receptor antagonist palonosetron, in the ...
Geneva/New York (ots) - Simon Hobbs spoke with WISeKey CEO Carlos Moreira yesterday about protecting personal data. Discussing "the right to disappear," Simon Hobbs asked founder Moreira about WISeKey's encryption technology which offers governments, companies, and individuals services that protect data, ...
Lugano, Switzerland/Tokyo, Japan (ots) - License Agreement for Japan on Potential New Therapy in the Prevention of Chemotherapy-induced Nausea and Vomiting (CINV) Helsinn Group of Switzerland and Taiho Pharmaceutical Co., Ltd., Japanese licensee of Helsinn's second generation 5-HT3 receptor antagonist palonosetron, announce today the signing on April 12, of a licensing agreement granting Taiho the development and ...
Geneva, Switzerland (ots) - WISeID V2.3 Personal Data Protector is a unique application for the protection of personal data and personal identifiable information (PII). Now with the release of WISeID Version 2.3 on 25 March, WISeID has integrated Facebook Connect, offering users control of to their profile. The next ...
Winterthur (ots) - FLSmidth MAAG Gear AG of Winterthur Switzerland, a supplier to the cement and minerals industry, is launching a new drive concept at the Hannover Messe trade fair. In the novel, integrated and modular MAAG CEM Drive, this company combines the advantages of proven MAAG gear technology with an ingenious motor concept, all inside one common ...
Hitachi Medical Systems Europe Holding AG
Geneva (ots) - WISeKey, a leading eSecurity company, and Switzerland's leading English-language magazine, Swiss Style, have joined forces to introduce WISeSwissStyle: a revolutionary iPad app for high-scale events that wish to offer WISeID personal data protection and to broadcast content and make event-related applications available for participants. This ...
Geneva (ots) - From now on, watches will be protected by a SmartCard and a digital certificate provided by WISeKey, proving their identity and origin. This innovative solution presented today at the Geneva Time Exhibition by WISeKey represents another decisive step in the fight against the sale of fakes. It consists of offering WISeAuthentic in the form ...
Lugano, Switzerland/Woodcliff Lake, NJ (ots) - Helsinn Group and Eisai Inc. announced today that the U.S. Food and Drug Administration (FDA) has agreed to the safety and efficacy protocols for Phase III trials with an investigational oral fixed-dose combination of netupitant and palonosetron in the prevention ...
Lugano, Switzerland (ots) - Helsinn Birex Pharmaceuticals Ltd, has been assigned world-wide rights, title and interest in Klean-Prep®, excluding Canada, and an exclusive license for the U.S. Helsinn, a pharmaceutical group based in Lugano, Switzerland today announced that it has entered into an agreement ...
Ittigen, Berne (ots) - Pevion Biotech AG today announced positive preliminary results from a Phase I study of PEV7, the first vaccine against recurrent vulvovaginal candidiasis (RVVC). Also known as chronic recurrent thrush, RVVC is a highly debilitating condition, which affects an estimated 3-6% of women ...
Singapore (ots) - WISeKey provides the aerospace and defense industry's only PKI (public key infrastructure) -based communications bridge where information can be stored and shared widely, securely, effectively and affordably between defense partners, suppliers and customers. WISeKey has built a special ...
Lugano (ots) - New data presented at the ESMO Milan 2010 Congress show a better control of nausea and vomiting with palonosetron versus granisetron in patients undergoing cisplatin or anthracycline plus cyclophosphamide based regimens. Palonosetron superior efficacy is statistically significant in nausea control, following Highly Emetogenic Chemotherapy, in the ...
Geneva (ots) - WISeID for iPhones and iPod Touch provides convenient, easy to use, encrypted storage for your identity credentials. WISeID's easy to use interface allows users to store their credentials and passwords securely on your iPhone, and easily logon to protected web-sites and communities such as Google, Facebook, Twitter, etc. Users can quickly ...
Lugano (ots) - The second generation 5-HT3 receptor antagonist palonosetron, already approved as an intravenous solution formulation in more than 60 countries worldwide including US, EU and Japan, obtains the European Marketing Authorization for 0.5 mg oral capsules Palonosetron 0.5 mg soft gelatine capsule oral formulation has been approved by the EMA (European Medicine Agency) for the prevention of nausea and ...
Lugano (ots) - New therapeutic option for the management of painful symptoms of oral mucositis in the oncology setting soon available for Swiss patients Helsinn, the pharmaceutical group based in Lugano, and Vifor Pharma, are pleased to announce that a Distribution & Licensing Agreement for Helsinn's product Gelclair in Switzerland has been signed recently. ...
Zug (ots) - The Swiss AmVac AG, a biopharmaceutical company located in Zug, has made significant advances in the manufacture and production of its vaccine candidate against RSV over the last few months. This vaccine candidate is based on the new Sendai vector technology for which Max-Planck-Innovations GmbH has acquired the exclusive licence. This technology, which has been developed by Prof. Wolfgang Neubert's ...
Zurich (ots) - Solianis Monitoring AG presents its Non-Invasive, Continuous Glucose Monitoring System at the 3rd International Conference on Advanced Technologies and Treatments for Diabetes (Basel, Switzerland, February 10-13, 2010). Dr. Andreas Caduff, PhD, Chief Technology Officer of Solianis, will present the concept of Solianis' proprietary ...
Lugano/Tokyo, Japan (ots) - The second generation 5-HT3 receptor antagonist palonosetron available in more than 50 countries worldwide, including US, EU and Japan Today, Taiho Pharmaceutical Co., Ltd., Japanese licensee of Helsinn's second generation 5-HT3 receptor antagonist palonosetron, gained marketing approval in Japan for this drug indicated for the ...
Saint-Prex, Switzerland (ots) - Results from a phase III pivotal study sub-analyses reported in European Urology show that prostate cancer patients who received Firmagon® (degarelix) in the study have a statistically significant greater probability of PSA (prostate-specific-antigen) recurrence-free survival ...